首页> 外文期刊>海南医科大学学报(英文版) >Effects of alprostadil combined with nucleoside antiviral drugs on liver function, liver fibrosis markers and serum inflammatory factors in patients with decompensated liver cirrhosis with HBV infection
【24h】

Effects of alprostadil combined with nucleoside antiviral drugs on liver function, liver fibrosis markers and serum inflammatory factors in patients with decompensated liver cirrhosis with HBV infection

机译:前列地尔联合核苷类抗病毒药对失代偿性肝硬化合并HBV感染患者肝功能,肝纤维化指标和血清炎性因子的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Objective:To explore the Effects of alprostadil combined with nucleoside antiviral drugs on liver function, liver fibrosis markers and serum inflammatory factors in patients with decompensated liver cirrhosis with HBV infection.Methods: 136 patients with decompensated cirrhosis of HBV infection who were hospitalized in Linxi Hospital of Kailuan General Hospital, Tangshan Infectious Disease Hospital and North China University of Technology Hospital from January to February 2018, 2017 were selected. All patients were divided into control group and case group by random number table method, 68 cases in each group. The control group was treated with routine liver protection and antiviral therapy, while the case group was treated with alprostadil on the basis of the control group. The changes of liver function, liver fibrosis, liver and spleen imaging indexes, anti-virus related indexes and inflammatory factors were observed before and after treatment in the two groups.Results: The total effective rate of the case group was 97.06%, which was significantly higher than that of the control group (85.29%), and the difference was statistically significant. The ALT, AST, TBIL, LN, HA, PCIII, CIV, portal vein diameter, spleen vein diameter, spleen thickness, IL-6, hs-CRP, TNF-α and TGF-β1 were significantly lower in the case group than in the control group. ALB, HBV DNA conversion rate, HBsAg negative rate, and HBeAg negative rate were significantly higher than the control group, the difference was statistically significant. Conclusion: Alprostadil combined with nucleoside antiviral drugs can significantly improve the decompensation of HBV infection Liver function in patients with cirrhosis, reduce the degree of liver fibrosis, inhibit the production of serum inflammatory factors, and can effectively inhibit HBV replication, clinical efficacy is significant, with certain clinical application value.
机译:目的:探讨前列地尔联合核苷类抗病毒药物对失代偿期肝硬化合并HBV感染患者肝功能,肝纤维化指标和血清炎性因子的影响。方法:136例肝硬化失代偿肝硬化患者在临溪医院住院入选2017年1月至2018年2月在开lu总医院,唐山传染病医院和华北理工大学医院工作的医院。采用随机数字表法将所有患者分为对照组和病例组,每组68例。对照组接受常规肝保护和抗病毒治疗,而病例组在对照组的基础上接受前列地尔治疗。观察两组治疗前后肝功能,肝纤维化,肝脾影像学指标,抗病毒相关指标和炎症因子的变化。结果:病例组总有效率97.06%,显着高于对照组(85.29%),差异有统计学意义。病例组的ALT,AST,TBIL,LN,HA,PCIII,CIV,门静脉直径,脾静脉直径,脾脏厚度,IL-6,hs-CRP,TNF-α和TGF-β1均显着低于对照组。对照组。 ALB,HBV DNA转化率,HBsAg阴性率和HBeAg阴性率均明显高于对照组,差异有统计学意义。结论:前列地尔联合核苷类抗病毒药可明显改善肝硬化患者的乙肝病毒感染失代偿能力,降低肝纤维化程度,抑制血清炎症因子的产生,并能有效抑制乙肝病毒复制,临床疗效显着,具有一定的临床应用价值。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2019年第8期|36-40|共5页
  • 作者单位

    Department of Infectious Diseases, Linxi Hospital, Kailuan General Hospital, Tangshan, Hebei Province, 063000, China;

    Department of Hepatology, Tangshan City Hospital for Infectious Diseases, Tangshan, Hebei Province, 063000, China;

    Department of Gastroenterology, Affiliated Hospital of North China University of Technology, Tangshan, Hebei Province, 063000, China;

    Second Department of Internal Medicine, Tangshan Fourth Hospital, Tangshan, Hebei Province, 063000, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 04:27:14
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号